Form 8-K MARAVAI LIFESCIENCES For: Nov 07
Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)
Company Research
Source: SEC EDGAR
Impact Snapshot
Event Time:
MRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRVI alerts
High impacting Maravai LifeSciences Holdings, Inc. - Class A common stock news events
Weekly update
A roundup of the hottest topics
MRVI
News
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock.MarketBeat
- Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of DirectorsGlobeNewswire
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $4.25 price target on the stock.MarketBeat
- Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer [Yahoo! Finance]Yahoo! Finance
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
MRVI
Earnings
- 11/7/24 - Beat
MRVI
Sec Filings
- 12/18/24 - Form 8-K
- 12/17/24 - Form 4
- 12/9/24 - Form 4
- MRVI's page on the SEC website